Exotoxins

Staphylococci in Human Disease: Second Edition

Volumn , Issue , 2009, Pages 125-146

  Schlievert, Patrick M ^a   Mccormick, John K ^b   Bohach, Gregory A ^c   Ohlendorf, Douglas H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF IDAHO   (United States)

Author keywords

Hemolysin 26 amino acid peptide and membrane damage; Biology and biochemistry of TSST 1; Cytotoxins; Exfoliative toxins A and B; Exotoxins; Massive T lymphocyte proliferation and superantigens; SFP and toxic shock syndrome differences; Srr, "master switch" regulator of exotoxin production; Staphylococcus aureus versatile organism causing human diseases; TSST 1 member of family of superantigens and staphylococcal enterotoxin like proteins

Indexed keywords

EID: 84859534888     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444308464.ch6     Document Type: Chapter

References (233)

1. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001;55:77-104.
2. Bergdoll MS, Schlievert PM. Toxic-shock syndrome toxin. Lancet 1984;ii:691.
3. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990;248:705-11.
4. McCormick JK, Bohach GA, Schlievert PM. Pyrogenic, lethal, and emetic properties of superantigens in rabbits and primates. Methods Mol Biol 2003;214:245-53.
5. Lina G, Bohach GA, Nair SP et al. Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis 2004;189:2334-6.
6. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993;54:99-166.
7. Choi Y, Lafferty JA, Clements JR et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 1990;172:981-4.
8. Bueno C, Lemke CD, Criado G et al. Bacterial superantigens bypass Lck-dependent T cell receptor signaling by activating a Galpha11-dependent, PLC-beta-mediated pathway. Immunity 2006;25:67-78.
9. Dinges MM, Gregerson DS, Tripp TJ, McCormick JK, Schlievert PM. Effects of total body irradiation and cyclosporin A on the lethality of toxic shock syndrome toxin-1 in a rabbit model of toxic shock syndrome. J Infect Dis 2003;188:1142-5.
10. Hofer MF, Harbeck RJ, Schlievert PM, Leung DY. Staphylococcal toxins augment specific IgE responses by atopic patients exposed to allergen. J Invest Dermatol 1999;112:171-6.
11. Hofer MF, Lester MR, Schlievert PM, Leung DY. Upregulation of IgE synthesis by staphylococcal toxic shock syndrome toxin- 1 in peripheral blood mononuclear cells from patients with atopic dermatitis. Clin Exp Allergy 1995;25:1218-27.
12. Schlievert PM. Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect Immun 1982;36:123-8.
13. Schlievert PM, Bettin KM, Watson DW. Inhibition of ribonucleic acid synthesis by group A streptococcal pyrogenic exotoxin. Infect Immun 1980;27:542-8.
14. Fiume L, Stirpe F. Decreased RNA content in mouse liver nuclei after intoxication with alpha-amanitin. Biochim Biophys Acta 1966;123:643-5.
15. Chow AW, Bartlett KH, Percival-Smith R, Morrison BJ. Vaginal colonization with Staphylococcus aureus, positive for toxicshock marker protein, and Escherichia coli in healthy women. J Infect Dis 1984;150:80-4.
16. Dinges MM, Schlievert PM. Comparative analysis of lipopolysaccharide- induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1. Infect Immun 2001;69:7169-72.
17. Sauter C, Wolfensberger C. Interferon in human serum after injection of endotoxin. Lancet 1980;ii:852-3.
18. Kushnaryov VM, MacDonald HS, Reiser RF, Bergdoll MS. Reaction of toxic shock syndrome toxin 1 with endothelium of human umbilical cord vein. Rev Infect Dis 1989;11(suppl 1): S282-S287; discussion S287-S288.
19. Lee PK, Vercellotti GM, Deringer JR, Schlievert PM. Effects of staphylococcal toxic shock syndrome toxin 1 on aortic endothelial cells. J Infect Dis 1991;164:711-19.
20. Lee PK, Deringer JR, Kreiswirth BN, Novick RP, Schlievert PM. Fluid replacement protection of rabbits challenged subcutaneously with toxic shock syndrome toxins. Infect Immun 1991;59:879-84.
21. Parsonnet J, Gillis ZA, Richter AG, Pier GB. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun 1987;55:1070-6.
22. Giantonio BJ, Alpaugh RK, Schultz J et al. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol 1997;15:1994-2007.
23. Kaul R, McGeer A, Norrby-Teglund A et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999;28:800-7.
24. Schlievert PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 2001; 108:107S-110S.
25. Schwab JH, Watson DW, Cromartie WJ. Further studies of group A streptococcal factors with lethal and cardiotoxic properties. J Infect Dis 1955;96:14-18.
26. Keane WF, Gekker G, Schlievert PM, Peterson PK. Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1. Am J Pathol 1986;122:169-76.
27. Leonard BA, Schlievert PM. Immune cell lethality induced by streptococcal pyrogenic exotoxin A and endotoxin. Infect Immun 1992;60:3747-55.
28. Mitchell DT, Levitt DG, Schlievert PM, Ohlendorf DH. Structural evidence for the evolution of pyrogenic toxin superantigens. J Mol Evol 2000;51:520-31.
29. Todd JK, Kapral FA, Fishaut M, Welch TR. Toxic shock syndrome associated with phage group 1 staphylococci. Lancet 1978;ii:1116-18.
30. Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 1980;303:1429-35.
31. Osterholm MT, Davis JP, Gibson RW et al. Tri-state toxic-state syndrome study. I. Epidemiologic findings. J Infect Dis 1982;145:431-40.
32. Shands KN, Schmid GP, Dan BB et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 1980;303:1436 -42.
33. Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet 1981;i:1017-21.
34. Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis 1981;143:509-16.
35. Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol 2004;42:2875-6.
36. Schlievert PM, Kim MH. Reporting of toxic shock syndrome Staphylococcus aureus in 1982 to 1990. J Infect Dis 1991; 164:1245-6.
37. Schlievert PM. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with nonmenstrual TSS. Lancet 1986;i:1149-50.
38. Kreiswirth BN, Schlievert PM, Novick RP. Evaluation of coagulase-negative staphylococci for ability to produce toxic shock syndrome toxin 1. J Clin Microbiol 1987;25:2028-9.
39. Lindsay JA, Ruzin A, Ross HF, Kurepina N, Novick RP. The gene for toxic shock toxin is carried by a family of mobile pathogenicity islands in Staphylococcus aureus. Mol Microbiol 1998;29:527-43.
40. Blomster-Hautamaa DA, Kreiswirth BN, Kornblum JS, Novick RP, Schlievert PM. The nucleotide and partial amino acid sequence of toxic shock syndrome toxin-1. J Biol Chem 1986;261:15783-6.
41. Blomster-Hautamaa DA, Kreiswirth BN, Novick RP, Schlievert PM. Resolution of highly purified toxic-shock syndrome toxin 1 into two distinct proteins by isoelectric focusing. Biochemistry 1986;25:54-9.
42. Blomster-Hautamaa DA, Schlievert PM. Preparation of toxic shock syndrome toxin-1. Methods Enzymol 1988;165:37-43.
43. Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003; 48:1429-49.
44. Recsei P, Kreiswirth B, O'Reilly M, Schlievert P, Gruss A, Novick RP. Regulation of exoprotein gene expression in Staphylococcus aureus by agr. Mol Gen Genet 1986;202:58-61.
45. Blomster-Hautamaa DA, Novick RP, Schlievert PM. Localization of biologic functions of toxic shock syndrome toxin-1 by use of monoclonal antibodies and cyanogen bromidegenerated toxin fragments. J Immunol 1986;137:3572-6.
46. Pragman AA, Schlievert PM. Virulence regulation in Staphylococcus aureus: the need for in vivo analysis of virulence factor regulation. FEMS Immunol Med Microbiol 2004;42:147- 54.
47. Yarwood JM, Schlievert PM. Quorum sensing in Staphylococcus infections. J Clin Invest 2003;112:1620-5.
48. Steinhuber A, Goerke C, Bayer MG, Doring G, Wolz C. Molecular architecture of the regulatory locus sae of Staphylococcus aureus and its impact on expression of virulence factors. J Bacteriol 2003;185:6278-86.
49. Giraudo AT, Cheung AL, Nagel R. The sae locus of Staphylococcus aureus controls exoprotein synthesis at the transcriptional level. Arch Microbiol 1997;168:53-8.
50. Giraudo AT, Mansilla C, Chan A, Raspanti C, Nagel R. Studies on the expression of regulatory locus sae in Staphylococcus aureus. Curr Microbiol 2003;46:246-50.
51. Giraudo AT, Raspanti CG, Calzolari A, Nagel R. Characterization of a Tn551-mutant of Staphylococcus aureus defective in the production of several exoproteins. Can J Microbiol 1994;40:677-81.
52. Dunman PM, Murphy E, Haney S et al. Transcription profilingbased identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol 2001;183:7341-53.
53. Bayer AS, Ramos MD, Menzies BE, Yeaman MR, Shen AJ, Cheung AL. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect Immun 1997;65:4652-60.
54. Cheung AL, Bayer MG, Heinrichs JH. sar genetic determinants necessary for transcription of RNAII and RNAIII in the agr locus of Staphylococcus aureus. J Bacteriol 1997;179:3963-71.
55. Cheung AL, Koomey JM, Butler CA, Projan SJ, Fischetti VA. Regulation of exoprotein expression in Staphylococcus aureus by a locus (sar) distinct from agr. Proc Natl Acad Sci USA 1992;89:6462-6.
56. Cheung AL, Schmidt K, Bateman B, Manna AC. SarS, a SarA homolog repressible by agr, is an activator of protein A synthesis in Staphylococcus aureus. Infect Immun 2001;69:2448-55.
57. Cheung AL, Ying P. Regulation of alpha- and beta-hemolysins by the sar locus of Staphylococcus aureus. J Bacteriol 1994; 176:580-5.
58. Cheung AL, Zhang G. Global regulation of virulence determinants in Staphylococcus aureus by the SarA protein family. Front Biosci 2002;7:d1825-d1842.
59. Chien Y, Cheung AL. Molecular interactions between two global regulators, sar and agr, in Staphylococcus aureus. J Biol Chem 1998;273:2645-52.
60. Chien Y, Manna AC, Projan SJ, Cheung AL. SarA, a global regulator of virulence determinants in Staphylococcus aureus, binds to a conserved motif essential for sar-dependent gene regulation. J Biol Chem 1999;274:37169-76.
61. Chan PF, Foster SJ. Role of SarA in virulence determinant production and environmental signal transduction in Staphylococcus aureus. J Bacteriol 1998;180:6232-41.
62. Chan PF, Foster SJ, Ingham E, Clements MO. The Staphylococcus aureus alternative sigma factor sB controls the environmental stress response but not starvation survival or pathogenicity in a mouse abscess model. J Bacteriol 1998; 180:6082-9.
63. Deora R, Tseng T, Misra TK. Alternative transcription factor sB of Staphylococcus aureus: characterization and role in transcription of the global regulatory locus sar. J Bacteriol 1997;179:6355-9.
64. Heinrichs JH, Bayer MG, Cheung AL. Characterization of the sar locus and its interaction with agr in Staphylococcus aureus. J Bacteriol 1996;178:418-23.
65. Manna AC, Cheung AL. sarU, a sarA homolog, is repressed by SarT and regulates virulence genes in Staphylococcus aureus. Infect Immun 2003;71:343-53.
66. Manna AC, Cheung AL. Expression of SarX, a negative regulator of agr and exoprotein synthesis, is activated by MgrA in Staphylococcus aureus. J Bacteriol 2006;188:4288-99.
67. Rechtin TM, Gillaspy AF, Schumacher MA, Brennan RG, Smeltzer MS, Hurlburt BK. Characterization of the SarA virulence gene regulator of Staphylococcus aureus. Mol Microbiol 1999;33:307-16.
68. Schmidt KA, Manna AC, Gill S, Cheung AL. SarT, a repressor of a-hemolysin in Staphylococcus aureus. Infect Immun 2001; 69:4749-58.
69. Tormo MA, Martí M, Valle J et al. SarA is an essential positive regulator of Staphylococcus epidermidis biofilm development. J Bacteriol 2005;187:2348-56.
70. Pragman AA, Herron-Olson L, Case LC et al. Sequence analysis of the Staphylococcus aureus srrAB loci reveals that truncation of srrA affects growth and virulence factor expression. J Bacteriol 2007;189:7515-19.
71. Pragman AA, Yarwood JM, Tripp TJ, Schlievert PM. Characterization of virulence factor regulation by SrrAB, a two-component system in Staphylococcus aureus. J Bacteriol 2004;186:2430-8.
72. Yarwood JM, McCormick JK, Schlievert PM. Identification of a novel two-component regulatory system that acts in global regulation of virulence factors of Staphylococcus aureus. J Bacteriol 2001;183:1113-23.
73. Said-Salim B, Dunman PM, McAleese FM et al. Global regulation of Staphylococcus aureus genes by Rot. J Bacteriol 2003;185:610-19.
74. Fournier B, Klier A, Rapoport G. The two-component system ArlS-ArlR is a regulator of virulence gene expression in Staphylococcus aureus. Mol Microbiol 2001;41:247-61.
75. Luong TT, Newell SW, Lee CY. Mgr, a novel global regulator in Staphylococcus aureus. J Bacteriol 2003;185:3703-10.
76. Garvis S, Mei JM, Ruiz-Albert J, Holden DW. Staphylococcus aureus svrA: a gene required for virulence and expression of the agr locus. Microbiology 2002;148:3235-43.
77. Schlievert PM, Case LC, Nemeth KA et al. Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. Biochemistry 2007;46:14349-58.
78. Peng HL, Novick RP, Kreiswirth B, Kornblum J, Schlievert P. Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. J Bacteriol 1988; 170:4365-72.
79. Cheung AL, Projan SJ. Cloning and sequencing of sarA of Staphylococcus aureus, a gene required for the expression of agr. J Bacteriol 1994;176:4168-72.
80. Schlievert PM, Blomster DA. Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors. J Infect Dis 1983;147:236-42.
81. Acharya KR, Passalacqua EF, Jones EY et al. Structural basis of superantigen action inferred from crystal structure of toxicshock syndrome toxin-1. Nature 1994;367:94-7.
82. Prasad GS, Earnhart CA, Murray DL, Novick RP, Schlievert PM, Ohlendorf DH. Structure of toxic shock syndrome toxin 1. Biochemistry 1993;32:13761-6.
83. Kim J, Urban RG, Strominger JL, Wiley DC. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 1994;266:1870-4.
84. Hurley JM, Shimonkevitz R, Hanagan A et al. Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1. J Exp Med 1995;181:2229-35.
85. Moza B, Buonpane RA, Zhu P et al. Long-range cooperative binding effects in a T cell receptor variable domain. Proc Natl Acad Sci USA 2006;103:9867-72.
86. Moza, B. Varma AK, Buonpane RA et al. Structural basis of T-cell specificity and activation by the bacterial superantigen TSST-1. EMBO J 2007;26:1187-97.
87. Murray DL, Earhart CA, Mitchell DT, Ohlendorf DH, Novick RP, Schlievert PM. Localization of biologically important regions on toxic shock syndrome toxin 1. Infect Immun 1996;64:371-4.
88. Murray DL, Prasad GS, Earhart CA et al. Immunobiologic and biochemical properties of mutants of toxic shock syndrome toxin-1. J Immunol 1994;152:87-95.
89. McCormick JK, Tripp TJ, Llera AS et al. Functional analysis of the TCR binding domain of toxic shock syndrome toxin-1 predicts further diversity in MHC class II/superantigen/TCR ternary complexes. J Immunol 2003;171:1385-92.
90. Bonventre PF, Heeg H, Edwards CK III, Cullen CM. A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity. Infect Immun 1995;63:509-15.
91. Davis CC, Kremer MJ, Schlievert PM, Squier CA. Penetration of toxic shock syndrome toxin-1 across porcine vaginal mucosa ex vivo: permeability characteristics, toxin distribution, and tissue damage. Am J Obstet Gynecol 2003;189:1785- 91.
92. Squier CA, Mantz MJ, Schlievert PM, Davis CC. Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J Pharm Sci 2008;97:9-21.
93. Peterson M, Ault K, Kremer MJ et al. Innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin-1. Infect Immun 2005;73:2164-74.
94. Kushnaryov VM, MacDonald HS, Reiser R, Bergdoll MS. Staphylococcal toxic shock toxin specifically binds to cultured human epithelial cells and is rapidly internalized. Infect Immun 1984;45:566-71.
95. Schlievert PM, Jablonski LM, Roggiani M et al. Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals. Infect Immun 2000;68:3630-34.
96. Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley MJ. Lack of complete correlation between emetic and T-cell-stimulatory activities of staphylococcal enterotoxins. Infect Immun 1993;61:3175-83.
97. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000;13:16-34.
98. Hovde CJ, Hackett SP, Bohach GA. Nucleotide sequence of the staphylococcal enterotoxin C3 gene: sequence comparison of all three type C staphylococcal enterotoxins. Mol Gen Genet 1990;220:329-33.
99. Turner TN, Smith CL, Bohach GA. Residues 20, 22, and 26 determine the subtype specificities of staphylococcal enterotoxins C1 and C2. Infect Immun 1992;60:694-7.
100. Marr JC, Lyon JD, Roberson JR, Lupher M, Davis WC, Bohach GA. Characterization of novel type C staphylococcal enterotoxins: biological and evolutionary implications. Infect Immun 1993;61:4254-62.
101. Deringer JR, Ely RJ, Stauffacher CV, Bohach GA. Subtypespecific interactions of type C staphylococcal enterotoxins with the T-cell receptor. Mol Microbiol 1996;22:523-34.
102. Edwards VM, Deringer JR, Callantine SD et al. Characterization of the canine type C enterotoxin produced by Staphylococcus intermedius pyoderma isolates. Infect Immun 1997;65: 2346-52.
103. Fields BA, Malchiodi EL, Li H et al. Crystal structure of a T-cell receptor beta-chain complexed with a superantigen. Nature 1996;384:188-92.
104. Andersen PS, Lavoie PM, Séklay RP et al. Role of the T cell receptor alpha chain in stabilizing TCR-superantigen-MHC class II complexes. Immunity 1999;10:473-83.
105. Leder L, Llera A, Lavoie PM et al. A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II. J Exp Med 1998;187:823-33.
106. Malchiodi EL, Eisenstein E, Fields BA et al. Superantigen binding to a T cell receptor beta chain of known three-dimensional structure. J Exp Med 1995;182:1833-45.
107. Li H, Llera A, Tsuchiya D et al. Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity 1998; 9:807-16.
108. Li H, Llera A, Malchiodi EL, Mariuzza RA. The structural basis of T cell activation by superantigens. Annu Rev Immunol 1999;17:435-66.
109. Hovde CJ, Marr JC, Hoffmann ML et al. Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1. Mol Microbiol 1994;13:897-909.
110. Sundström M, Hallén D, Svensson A et al. The co-crystal structure of staphylococcal enterotoxin type A with Zn2+ at 2.7 Å resolution. Implications for major histocompatibility complex class II binding. J Biol Chem 1996;271:32212-16.
111. Schad EM, Papageorgiou AC, Svensson LA, Acharya KR. A structural and functional comparison of staphylococcal enterotoxins A and C2 reveals remarkable similarity and dissimilarity. J Mol Biol 1997;269:270-80.
112. Li Y, Li H, Dimasi N et al. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity 2001;14:93-104.
113. Sundberg EJ, Li H, Llera AS et al. Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexes. Structure 2002;10:687-99.
114. Petersson K, Pettersson H, Skartved NJ, Walse B, Forsberg G. Staphylococcal enterotoxin H induces V alpha-specific expansion of T cells. J Immunol 2003;170:4148-54.
115. Pumphrey N, Vuidepot A, Jakobsen B, Forsberg G, Walse B, Lindkvist-Petersson K. Cutting edge: Evidence of direct TCR alpha-chain interaction with superantigen. J Immunol 2007; 179:2700-4.
116. Brouillard JN, Günther S, Varma AK et al. Crystal structure of the streptococcal superantigen SpeI and functional role of a novel loop domain in T cell activation by group V superantigens. J Mol Biol 2007;367:925-34.
117. Orwin PM, Fitzgerald JR, Leung DY, Gutierrez JA, Bohacj GA, Schlievert PM. Characterization of Staphylococcus aureus enterotoxin L. Infect Immun 2003;71:2916-19.
118. Orwin PM, Leung DY, Donahue HL, Novick RP, Schlievert PM. Biochemical and biological properties of staphylococcal enterotoxin K. Infect Immun 2001;69:360-6.
119. Orwin PM, Leung DY, Tripp TJ et al. Characterization of a novel staphylococcal enterotoxin-like superantigen, a member of the group V subfamily of pyrogenic toxins. Biochemistry 2002;41:14033-40.
120. Günther S, Varma AK, Moza B et al. A novel loop domain in superantigens extends their T cell receptor recognition site. J Mol Biol 2007;371:210-21.
121. Holmberg SD, Blake PA. Staphylococcal food poisoning in the United States. New facts and old misconceptions. JAMA 1984;251:487-9.
122. Kent TH. Staphylococcal enterotoxin gastroenteritis in rhesus monkeys. Am J Pathol 1966;48:387-407.
123. Sugiyama H, Hayama T. Abdominal viscera as site of emetic action for staphylococcal enterotoxin in the monkey. J Infect Dis 1965;115:330-6.
124. Jett M, Brinkley W, Neill R, Gemski P, Hunt R. Staphylococcus aureus enterotoxin B challenge of monkeys: correlation of plasma levels of arachidonic acid cascade products with occurrence of illness. Infect Immun 1990;58:3494-9.
125. Scheuber PH, Golecki JR, Kickhöfen B, Scheel D, Beck G, Hammer DK. Skin reactivity of unsensitized monkeys upon challenge with staphylococcal enterotoxin B: a new approach for investigating the site of toxin action. Infect Immun 1985;50:869-76.
126. Reck B, Scheuber PH, Longdong W, Sailer-Kramer B, Bartsch K, Hammer DK. Protection against the staphylococcal enterotoxin- induced intestinal disorder in the monkey by antiidiotypic antibodies. Proc Natl Acad Sci USA 1988;85:3170-4.
127. Komisar J, Rivera J, Vega A, Tseng J. Effects of staphylococcal enterotoxin B on rodent mast cells. Infect Immun 1992;60: 2969-75.
128. Alber G, Hammer DK, Fleischer B. Relationship between enterotoxic- and T lymphocyte-stimulating activity of staphylococcal enterotoxin B. J Immunol 1990;144:4501-6.
129. Alber G, Scheuber PH, Reck B, Sailer-Kramer B, Hartmann A, Hammer DK. Role of substance P in immediate-type skin reactions induced by staphylococcal enterotoxin B in unsensitized monkeys. J Allergy Clin Immunol 1989;84:880-5.
130. Beery JT, Taylor SL, Schlunz LR, Freed RC, Bergdoll MS. Effects of staphylococcal enterotoxin A on the rat gastrointestinal tract. Infect Immun 1984;44:234-40.
131. Bergdoll MS. Monkey feeding test for staphylococcal enterotoxin. Methods Enzymol 1988;165:324-33.
132. Wright A, Andrews PL, Titball RW. Induction of emetic, pyrexic, and behavioral effects of Staphylococcus aureus enterotoxin B in the ferret. Infect Immun 2000;68:2386-9.
133. van Gessel YA, Mani S, Bi S et al. Functional piglet model for the clinical syndrome and postmortem findings induced by staphylococcal enterotoxin B. Exp Biol Med (Maywood) 2004; 229:1061-71.
134. Hu DL, Omoe K, Shimura H, Ono K, Sugii S, Shinagawa K. Emesis in the shrew mouse (Suncus murinus) induced by peroral and intraperitoneal administration of staphylococcal enterotoxin A. J Food Prot 1999;62:1350-3.
135. Iandolo JJ. Genetic analysis of extracellular toxins of Staphylococcus aureus. Annu Rev Microbiol 1989;43:375-402.
136. Buonpane RA, Churchhill HR, Moza B et al. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 2007;13:725-9.
137. Buonpane RA, Moza B, Sundberg EJ, Kranz DM. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1. J Mol Biol 2005;353:308- 21.
138. Schlievert PM, Bohach GA. Staphylococcal and streptococcal superantigens: an update. In: Kotb M, Fraser JD, eds. Superantigens. Molecular Basis for Their Role in Human Diseases. Washington, DC: American Society for Microbiology Press, 2007:21-36.
139. Fey PD, Said-Salim B, Rupp ME et al. Comparative molecular analysis of community- or hospital-acquired methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:196-203.
140. Tenover FC, Gaynes RP. The epidemiology of staphylococcus infection. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, eds. Gram-positive Pathogens. Washington, DC: American Society for Microbiology Press, 2000:414-21.
141. Ahrens P, Andresen LO. Cloning and sequence analysis of genes encoding Staphylococcus hyicus exfoliative toxin types A, B, C, and D. J Bacteriol 2004;186:1833-7.
142. Ladhani S. Recent developments in staphylococcal scalded skin syndrome. Clin Microbiol Infect 2001;7:301-7.
143. Yamasaki O, Tristan A, Yamaguchi T et al. Distribution of the exfoliative toxin D gene in clinical Staphylococcus aureus isolates in France. Clin Microbiol Infect 2006;12:585-8.
144. Melish ME, Glasgow LA. The staphylococcal scalded-skin syndrome. N Engl J Med 1970;282:1114-19.
145. Arbuthnott JP, Kent J, Lyell A, Gemmel CG. The role of extracellular products of 'phage group 2 staphylococci in toxic epidermal necrolysis. Contrib Microbiol Immunol 1973;1:434- 40.
146. Kapral FA, Miller MM. Product of Staphylococcus aureus responsible for the scalded-skin syndrome. Infect Immun 1971;4:541-5.
147. Kondo I, Sakurai S, Sarai Y. Purification of exfoliatin produced by Staphylococcus aureus of bacteriophage group 2 and its physicochemical properties. Infect Immun 1973;8:156-64.
148. Kondo I, Sakurai S, Sarai Y. New type of exfoliatin obtained from staphylococcal strains, belonging to phage groups other than group II, isolated from patients with impetigo and Ritter's disease. Infect Immun 1974;10:851-61.
149. Melish ME, Glasgow LA, Turner MD. The staphylococcal scalded-skin syndrome: isolation and partial characterization of the exfoliative toxin. J Infect Dis 1972;125:129-40.
150. Lee CY, Schmidt JJ, Johnson-Winegar AD, Spero L, Iandolo JJ. Sequence determination and comparison of the exfoliative toxin A and toxin B genes from Staphylococcus aureus. J Bacteriol 1987;169:3904-9.
151. Yamaguchi T, Hayashi T, Takami H et al. Phage conversion of exfoliative toxin A production in Staphylococcus aureus. Mol Microbiol 2000;38:694-705.
152. Yamaguchi T, Hayashi T, Takami H et al. Complete nucleotide sequence of a Staphylococcus aureus exfoliative toxin B plasmid and identification of a novel ADP-ribosyltransferase, EDIN-C. Infect Immun 2001;69:7760-71.
153. de Azavedo JC, Bailey CJ, Arbuthnott JP. Purification of epidermolytic toxin of Staphylococcus aureus. Methods Enzymol 1988;165:32-6.
154. Vath GM, Earhart CA, Monie DD, Iandolo JJ, Schlievert PM, Ohlendorf DH. The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity. Biochemistry 1999; 38:10239-46.
155. Vath GM, Earhart CA, Rago JV et al. The structure of the superantigen exfoliative toxin A suggests a novel regulation as a serine protease. Biochemistry 1997;36:1559-66.
156. Lillibridge CB, Melish ME, Glasgow LA. Site of action of exfoliative toxin in the staphylococcal scalded-skin syndrome. Pediatrics 1972;50:728-38.
157. Elias PM, Fritsch P, Dahl MV, Wolff K. Staphylococcal toxic epidermal necrolysis: pathogenesis and studies on the subcellular site of action of exfoliatin. J Invest Dermatol 1975; 65:501-12.
158. McLay AL, Arbuthnott JP, Lyell A. Action of staphylococcal epidermolytic toxin on mouse skin: an electron microscopic study. J Invest Dermatol 1975;65:423-8.
159. Wuepper KD, Dimond RL, Knutson DD. Studies of the mechanism of epidermal injury by a staphylococcal epidermolytic toxin. J Invest Dermatol 1975;65:191-200.
160. Baker DH, Dimond RL, Wuepper KD. The epidermolytic toxin of Staphylococcus aureus: its failure to bind to cells and its detection in blister fluids of patients with bullous impetigo. J Invest Dermatol 1978;71:274-5.
161. Rago JV, Vath GM, Bohach GA, Ohlendorf DH, Schlievert PM. Mutational analysis of the superantigen staphylococcal exfoliative toxin A (ETA). J Immunol 2000;164:2207-13.
162. Monday SR, Vath GM, Ferens WA et al. Unique superantigen activity of staphylococcal exfoliative toxins. J Immunol 1999; 162:4550-9.
163. Fleischer B, Bailey CJ. Recombinant epidermolytic (exfoliative) toxin A of Staphylococcus aureus is not a superantigen. Med Microbiol Immunol 1992;180:273-8.
164. Smith TP, John DA, Bailey CJ. The binding of epidermolytic toxin from Staphylococcus aureus to mouse epidermal tissue. Histochem J 1987;19:137-49.
165. Smith TP, John DA, Bailey CJ. Epidermolytic toxin binds to components in the epidermis of a resistant species. Eur J Cell Biol 1989;49:341-9.
166. Smith TP, Bailey CJ. Epidermolytic toxin from Staphylococcus aureus binds to filaggrins. FEBS Lett 1986;194:309-12.
167. Bailey CJ, Smith TP. The reactive serine residue of epidermolytic toxin A. Biochem J 1990;269:535-7.
168. Prevost G, Rifai S, Chaix ML, Piemont Y. Functional evidence that the Ser-195 residue of staphylococcal exfoliative toxin A is essential for biological activity. Infect Immun 1991;59:3337-9.
169. Rago JV, Vath GM, Tripp TJ, Bohach GA, Ohlendorf DH, Schlievert PM. Staphylococcal exfoliative toxins cleave alphaand beta-melanocyte-stimulating hormones. Infect Immun 2000;68:2366-8.
170. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000;6:1275-7.
171. Hanakawa Y, Schechter NM, Lin C, Nishifuji K, Amagai M, Stanley JR. Enzymatic and molecular characteristics of the efficiency and specificity of exfoliative toxin cleavage of desmoglein 1. J Biol Chem 2004;279:5268-77.
172. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol 2002;118:845-50.
173. Freer JH, Arbuthnott JP. Toxins of Staphylococcus aureus. Pharmacol Ther 1982;19:55-106.
174. Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev 1991;55:733- 51.
175. Gray GS, Kehoe M. Primary sequence of the alpha-toxin gene from Staphylococcus aureus Wood 46. Infect Immun 1984;46:615-18.
176. O'Reilly M, Kreiswirth B, Foster TJ. Cryptic alpha-toxin gene in toxic shock syndrome and septicaemia strains of Staphylococcus aureus. Mol Microbiol 1990;4:1947-55.
177. Bernheimer AW, Schwartz LL. Isolation and composition of staphylococcal alpha toxin. J Gen Microbiol 1963;30:455-68.
178. Harshman S, Boquet P, Duflot E, Alouf JE, Montecucco C, Papini E. Staphylococcal alpha-toxin: a study of membrane penetration and pore formation. J Biol Chem 1989;264:14978- 84.
179. Gouaux JE, Braha O, Hobaugh MR et al. Subunit stoichiometry of staphylococcal alpha-hemolysin in crystals and on membranes: a heptameric transmembrane pore. Proc Natl Acad Sci USA 1994;91:12828-31.
180. Bhakdi S, Muhly M, Fussle R. Correlation between toxin binding and hemolytic activity in membrane damage by staphylococcal alpha-toxin. Infect Immun 1984;46:318-23.
181. Bhakdi S, Valeva A, Walev I, Zitzer A, Palmer M. Pore-forming bacterial cytolysins. Symp Ser Soc Appl Microbiol 1998;27:15S- 25S.
182. Hildebrand A, Pohl M, Bhakdi S. Staphylococcus aureus alphatoxin. Dual mechanism of binding to target cells. J Biol Chem 1991;266:17195-200.
183. Cassidy P, Harshman S. Studies on the binding of staphylococcal 125I-labeled alpha-toxin to rabbit erythrocytes. Biochemistry 1976;15:2348-55.
184. Walev I, Martin E, Jonas D et al. Staphylococcal alpha-toxin kills human keratinocytes by permeabilizing the plasma membrane for monovalent ions. Infect Immun 1993;61:4972-9.
185. Jonas D, Walev I, Berger T, Liebetrau M, Palmer M, Bhakdi S. Novel path to apoptosis: small transmembrane pores created by staphylococcal alpha-toxin in T lymphocytes evoke internucleosomal DNA degradation. Infect Immun 1994;62:1304- 12.
186. Walev I, Plamer M, Martin E et al. Recovery of human fibroblasts from attack by the pore-forming alpha-toxin of Staphylococcus aureus. Microb Pathog 1994;17:187-201.
187. Walker B, Krishnasastry M, Zorn L, Kasianowicz J, Bayley H. Functional expression of the alpha-hemolysin of Staphylococcus aureus in intact Escherichia coli and in cell lysates. Deletion of five C-terminal amino acids selectively impairs hemolytic activity. J Biol Chem 1992;267:10902-9.
188. Suttorp N, Seeger W, Dewein E, Bhakdi S, Roka L. Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol 1985;248:C127-C134.
189. Suttorp N, Seeger W, Zucker-Reimann J, Roka L, Bhakdi S. Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun 1987; 55:104-10.
190. Seeger W, Birkemeyer RG, Ermert L, Suttorp N, Bhakdi S, Duncker HR. Staphylococcal alpha-toxin-induced vascular leakage in isolated perfused rabbit lungs. Lab Invest 1990;63: 341-9.
191. Glenny A, Stevens NF. Staphylococcal toxins and antitoxins. J Pathol Bacteriol 1935;40:201.
192. Coleman DC, Arbuthnott JP, Pomeroy HM, Birkbeck TH. Cloning and expression in Escherichia coli and Staphylococcus aureus of the beta-lysin determinant from Staphylococcus aureus: evidence that bacteriophage conversion of beta-lysin activity is caused by insertional inactivation of the beta-lysin determinant. Microb Pathog 1986;1:549-64.
193. Projan SJ, Kornblum J, Kreiswirth B, Moghazeh SL, Eisner W, Novick RP. Nucleotide sequence: the beta-hemolysin gene of Staphylococcus aureus. Nucleic Acids Res 1989;17:3305.
194. Doery HM, Magnusson BJ, Cheyne IM, Sulasekharam J. A phospholipase in staphylococcal toxin which hydrolyses sphingomyelin. Nature 1963;198:1091-2.
195. Huseby M, Shi K, Brown CK et al. Structure and biological activities of beta toxin from Staphylococcus aureus. J Bacteriol 2007;189:8719-26.
196. Low DK, Freer JH, Arbuthnott JP, Mollby R, Wadstrom T. Consequences of spingomyelin degradation in erythrocyte ghost membranes by staphylococcal beta-toxin (sphingomyelinase C). Toxicon 1974;12:279-85.
197. Marshall MJ, Bohach GA, Boehm DF. Characterization of Staphylococcus aureus beta-toxin induced leukotoxicity. J Nat Toxins 2000;9:125-38.
198. Woodin AM. Fractionation of a leucocidin from Staphylococcus aureus. Biochem J 1959;73:225-37.
199. Woodin AM. Purification of the two components of leucocidin from Staphylococcus aureus. Biochem J 1960;75:158-65.
200. Prévost G, Couppie P, Prévost P et al. Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995;42:237-45.
201. Barrio MB, Rainard P, Prévost G. LukM/LukF'-PV is the most active Staphylococcus aureus leukotoxin on bovine neutrophils. Microbes Infect 2006;8:2068-74.
202. Dalla Serra M, Coraiola M, Viero G et al. Staphylococcus aureus bicomponent gamma-hemolysins, HlgA, HlgB, and HlgC, can form mixed pores containing all components. J Chem Inf Model 2005;45:1539-45.
203. Bronner S, Monteil H, Prévost G. Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. FEMS Microbiol Rev 2004;28:183-200.
204. Menestrina G, Serra MD, Prévost G. Mode of action of beta-barrel pore-forming toxins of the staphylococcal alpha-hemolysin family. Toxicon 2001;39:1661-72.
205. Prévost G, Mourey L, Colin DA, Menestrina G. Staphylococcal pore-forming toxins. Curr Top Microbiol Immunol 2001;257: 53-83.
206. Szmigielski S, Prevost G, Monteil H, Colin DA, Jeljaszewicz J. Leukocidal toxins of staphylococci. Zentralbl Bakteriol 1999; 289:185-201.
207. Szmigielski S, Sobiczewska E, Prévost G, Monteil H, Colin DA, Jeljaszewicz J. Effect of purified staphylococcal leukocidal toxins on isolated blood polymorphonuclear leukocytes and peritoneal macrophages in vitro. Zentralbl Bakteriol 1998;288:383-94.
208. Ferreras M, Höper F, Dalla Serra M, Colin DA, Prévost G, Menestrina G. The interaction of Staphylococcus aureus bicomponent gamma-hemolysins and leucocidins with cells and lipid membranes. Biochim Biophys Acta 1998;1414:108-26.
209. Siqueira JA, Speeg-Schatz C, Freitas FI, Sahel J, Monteil H, Prévost G. Channel-forming leucotoxins from Staphylococcus aureus cause severe inflammatory reactions in a rabbit eye model. J Med Microbiol 1997;46:486-94.
210. Konig B, Prevost G, Konig W. Composition of staphylococcal bi-component toxins determines pathophysiological reactions. J Med Microbiol 1997;46:479-85.
211. Cooney J, Kienle Z, Foster TJ, O'Toole PW. The gammahemolysin locus of Staphylococcus aureus comprises three linked genes, two of which are identical to the genes for the F and S components of leukocidin. Infect Immun 1993;61:768- 71.
212. Cooney J, Mulvey M, Arbuthnott JP, Foster TJ. Molecular cloning and genetic analysis of the determinant for gammalysin, a two-component toxin of Staphylococcus aureus. J Gen Microbiol 1988;134:2179-88.
213. Plommet M. Preparation and purification of gamma-hemolysin of staphylococci. Methods Enzymol 1988;165:8-16.
214. Prevost G, Cribier B, Couppié P et al. Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun 1995;63:4121-9.
215. Noda M, Kato I. Purification and crystallization of staphylococcal leukocidin. Methods Enzymol 1988;165:22-32.
216. Guillet V, Roblin P, Werner S et al. Crystal structure of leucotoxin S component: new insight into the staphylococcal betabarrel pore-forming toxins. J Biol Chem 2004;279:41028-37.
217. Pedelacq JD, Maveyraud L, Prévost G et al. The structure of a Staphylococcus aureus leucocidin component (LukF-PV) reveals the fold of the water-soluble species of a family of transmembrane pore-forming toxins. Structure 1999;7:277-87.
218. Pedelacq JD, Prévost G, Monteil H, Mourey L, Samama JP. Crystal structure of the F component of the Panton-Valentine leucocidin. Int J Med Microbiol 2000;290:395-401.
219. Dufour P, Gillet Y, Bes M et al. Community-acquired methicillinresistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35:819-24.
220. Francis JS, Doherty MC, Lopatin U et al. Severe communityonset pneumonia in healthy adults caused by methicillinresistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:100-7.
221. Naimi TS, LeDell KH, Boxrud DJ et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001;33:990-6.
222. Voyich JM, Otto M, Mathema B et al. Is Panton-Valentine leukocidin the major virulence determinant in communityassociated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006;194:1761-70.
223. Labandeira-Rey M, Couzon F, Boisset S et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007;315:1130-3.
224. Wardenburg JB, Bae T, Otto M, DeLeo FR, Schneewind O. Poring over pores: alpha hemolysin and Panton Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007;13:1405-6.
225. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. JAMA 1999; 282:1123-5.
226. Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005;40:941-7.
227. Fitton JE, Dell A, Shaw WV. The amino acid sequence of the delta haemolysin of Staphylococcus aureus. FEBS Lett 1980; 115:209-12.
228. Birkbeck TH, Freer JH. Purification and assay of staphylococcal delta-lysin. Methods Enzymol 1988;165:16-22.
229. Freer JH, Birkbeck TH. Possible conformation of delta-lysin, a membrane-damaging peptide of Staphylococcus aureus. J Theor Biol 1982;94:535-40.
230. Dhople VM, Nagaraj R. Delta-toxin, unlike melittin, has only hemolytic activity and no antimicrobial activity: rationalization of this specific biological activity. Biosci Rep 1993;13:245- 50.
231. Lee KH, Fitton JE, Wuthrich K. Nuclear magnetic resonance investigation of the conformation of delta-haemolysin bound to dodecylphosphocholine micelles. Biochim Biophys Acta 1987;911:144-53.
232. Thelestam M, Mollby R. Determination of toxin-induced leakage of different-size nucleotides through the plasma membrane of human diploid fibroblasts. Infect Immun 1975;11:640-8.
233. Mellor IR, Thomas DH, Sansom MS. Properties of ion channels formed by Staphylococcus aureus delta-toxin. Biochim Biophys Acta 1988;942:280-94.